Download or read book New Zealand Biotechnology Business Models written by Timothy Keith McCready and published by . This book was released on 2007 with total page 260 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Business Modeling for Life Science and Biotech Companies written by Alberto Onetti and published by Routledge. This book was released on 2014-03-21 with total page 212 pages. Available in PDF, EPUB and Kindle. Book excerpt: Most books on the biotechnology industry focus on scientific and technological challenges, ignoring the entrepreneurial and managerial complexities faced bio-entrepreneurs. The Business Models for Life Science Firms aims to fill this gap by offering managers in this rapid growth industry the tools needed to design and implement an effective business model customized for the unique needs of research intensive organizations. Onetti and Zucchella begin by unpacking the often-used ‘business model’ term, examining key elements of business model conceptualization and offering a three tier approach with a clear separation between the business model and strategy: focus, exploring the different activities carried out by the organization; locus, evaluating where organizational activities are centered; and modus, testing the execution of the organization’s activities. The business model thus defines the unique way in which a company delivers on its promise to its customers. The theory and applications adopt a global approach, offering business cases from a variety of biotech companies around the world.

Download or read book Biotech Business Models and Their Alliance Capital written by Raphael Greiner and published by . This book was released on 2008 with total page 156 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Managing Biotechnology written by Francoise Simon and published by John Wiley & Sons. This book was released on 2017-10-16 with total page 322 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive overview of the new business context for biopharma companies, featuring numerous case studies and state-of-the-art marketing models Biotechnology has developed into a key innovation driver especially in the field of human healthcare. But as the biopharma industry continues to grow and expand its reach, development costs are colliding with aging demographics and cost-containment policies of private and public payers. Concurrently, the development and increased affordability of sophisticated digital technologies has fundamentally altered many industries including healthcare. The arrival of new information technology (infotech) companies on the healthcare scene presents both opportunities and challenges for the biopharma business model. To capitalize on new digital technologies from R&D through commercialization requires industry leaders to adopt new business models, develop new digital and data capabilities, and partner with innovators and payers worldwide. Written by two experts, both of whom have had decades of experience in the field, this book provides a comprehensive overview of the new business context and marketing models for biotech companies. Informed by extensive input by senior biotech executives and leading consultancies serving the industry, it analyzes the strategies and key success factors for the financing, development, and commercialization of novel therapeutic products, including strategies for engagement with patients, physicians and healthcare payers. Throughout case studies provide researchers, corporate marketers, senior managers, consultants, financial analysts, and other professionals involved in the biotech sector with insights, ideas, and models. JACQUALYN FOUSE, PhD, RETIRED PRESIDENT AND CHIEF OPERATING OFFICER, CELGENE “Biotech companies have long been innovators, using the latest technologies to enable cutting edge science to help patients with serious diseases. This book is essential to help biotech firms understand how they can–and must–apply the newest technologies including disruptive ones, alongside science, to innovate and bring new value to the healthcare system.” BRUCE DARROW, MD, PhD, CHIEF MEDICAL INFORMATION OFFICER, MOUNT SINAI HEALTH SYSTEM “Simon and Giovannetti have written an essential user’s manual explaining the complicated interplay of the patients who deserve cutting-edge medical care, the biotechnology companies (big and small) creating the breakthroughs, and the healthcare organizations and clinicians who bridge those worlds.” EMMANUEL BLIN, FORMER CHIEF STRATEGY OFFICER AND SENIOR VICE PRESIDENT, BRISTOL-MYERS SQUIBB “If you want to know where biopharma is going, read this book! Our industry is facing unprecedented opportunities driven by major scientific breakthroughs, while transforming itself to address accelerated landscape changes driven by digital revolutions and the emergence of value-based healthcare worldwide. In this ever-changing context, we all need to focus everything we do on the patients. They are why we exist as an industry, and this is ultimately what this insightful essay is really about.” JOHN MARAGANORE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALNYLAM PHARMACEUTICALS “Since the mapping of the human genome was completed nearly 15 years ago, the biotechnology industry has led the rapid translation of raw science to today’s innovative medicines. However, the work does not stop in the lab. Delivering these novel medicines to patients is a complex and multifaceted process, which is elegantly described in this new book.”

Download or read book Biotechnology in New Zealand a Business Perspective written by New Zealand. Department of Trade and Industry and published by . This book was released on 1988 with total page 68 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book The Design Factors for a New Zealand Biotechnology Cluster written by Pooja Bharamappa and published by . This book was released on 2018 with total page 93 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Bay Area biotech cluster, San Diego Biotech and Biovalley are familiar to a majority of the population – even those individuals who are not experts in the field can recall the successes of these communities. All three cases have humble beginnings and over the decades, have created local job opportunities and new business formation ultimately resulting in economic growth. New Zealand biotechnology has world-class potential, ranking number four in overall biotechnology potential according to the Scientific Worldview and outcompeting its Australian counterpart ranked at number five. However, New Zealand's biotech performance still lags behind the city of Melbourne, a city that is usually compared with Auckland due to the similarity in size. ASX-listed biotechnology companies are always valued much higher and are greater in number. How can New Zealand use its potential to increase biotechnology output? This study explores the possibility of implementing a cluster strategy for the New Zealand biotechnology industry. A qualitative exploratory methodology was used to explore the design factors for a NZ biotech cluster. This methodology was appropriate since it is a new mode of inquiry that has previously not been investigated. A conceptual framework was developed from the literature review resulting in three design factors to be considered: specialised or diversified cluster, geographical and relational proximity and cluster formation considerations. Primary findings gathered the perspectives of twelve biotechnology industry members through semi-structured interviews. Secondary findings gathered international cluster examples and critical factors for cluster formation in NZ to support the primary findings. Overall, participants leaned towards a diversified cluster which was in contrast with secondary findings, and a desire for international integration. They also discussed current strengths of the industry in line with critical factors for cluster formation, weaknesses of policy initiatives and how best to engage the private sector in the vision. These three sources of information converged to form important discussions on how such a strategy would apply in the New Zealand biotechnology context, resulting in six recommended design factors: 1) a strategy in favour of specialised clusters, 2) the use of virtual communications for international integration, 3) investing in absorptive capacity, 4) developing strong cluster branding, 5) engaging the private sector as the leader and 6) encouraging the public sector to create initiatives that strive for quality, increased specificity and long-term thinking.

Download or read book Blending Elements of Success written by Lakshmi Sethuraman and published by . This book was released on 2008 with total page 134 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book CEO Guide to Doing Business in New Zealand written by Ade Asefeso MCIPS MBA and published by AA Global Sourcing Ltd. This book was released on 2013-12-09 with total page 124 pages. Available in PDF, EPUB and Kindle. Book excerpt: New Zealand continues to lead the rankings for the Ease of Doing Business and for Starting a Business respectively. New Zealand has an open-market economy, a stable political system, and has been recognized as one of the world’s least-corrupt countries. This allows businesses to operate with confidence in New Zealand. Exporters to New Zealand should be prepared to adapt their business model to suit the nation’s small population and geographic isolation. New Zealand consists of several islands. The North Island and South Island, and a number of smaller islands with the capital and Government based in Wellington in the North Island. The resident population is approximately 4.4 million. New Zealand has an efficient market driven economy capable of delivering benefits to investors including business stability, extensive free trade agreements and active government support for investment. Investors can take advantage of a business environment consistently rated on many measures as one of the best in the world an environment where it is easy to commence business, where capital flows freely across borders and the quality of life is superb.

Download or read book European Perspectives on Green Biotechnology Business Practices written by Daniela Zirra and published by Cambridge Scholars Publishing. This book was released on 2024-04-24 with total page 162 pages. Available in PDF, EPUB and Kindle. Book excerpt: Many interesting publications can be found in the field of green biotechnology entrepreneurship, but most of them focus either on entrepreneurship in biotechnologies in general, or address industries that could benefit from the innovations brought about by green biotech. This book is a European approach to the subject, that starts from concepts and principles and moves to specific elements, promotion and management, financial aspects, achieved economic performances, information technology and communication tools that can be used for the initiation and development of a businesses in this sector, all the way up to a brief mapping of some good practices in different European countries. The book will be of interest to a wide range of readers, such as all those interested in starting and developing a business in this field, and also those who just wish to gather green biotech entrepreneurial knowledge, and to develop their skills and competencies in sustainable development.

Download or read book The Business of Bioscience written by Craig D. Shimasaki and published by Springer. This book was released on 2009-10-02 with total page 269 pages. Available in PDF, EPUB and Kindle. Book excerpt: My journey into this fascinating field of biotechnology started about 26 years ago at a small biotechnology company in South San Francisco called Genentech. I was very fortunate to work for the company that begat the biotech industry during its formative years. This experience established a solid foundation from which I could grow in both the science and business of biotechnology. After my fourth year of working on Oyster Point Boulevard, a close friend and colleague left Genentech to join a start-up biotechnology company. Later, he approached me to leave and join him in of all places – Oklahoma. He persisted for at least a year before I seriously considered his proposal. After listening to their plans, the opportunity suddenly became more and more intriguing. Finally, I took the plunge and joined this ent- preneurial team in cofounding and growing a start-up biotechnology company. Making that fateful decision to leave the security of a larger company was extremely difficult, but it turned out to be the beginning of an entrepreneurial career that forever changed how I viewed the biotechnology industry. Since that time, I have been fortunate to have cofounded two other biotechnology com- nies and even participated in taking one of them public. During my career in these start-ups, I held a variety of positions, from directing the science, operations, regulatory, and marketing components, to subsequently becoming CEO.

Download or read book Beyond Relocation written by Yahn-Zhih (James) Lin and published by . This book was released on 2014 with total page 160 pages. Available in PDF, EPUB and Kindle. Book excerpt: The commercialisation of innovative technologies is a key strategy for nations around the world from which economic prosperity can be derived. High-tech biotechnology is one area which has consistently been the focus of attention by many countries including New Zealand (NZ). Large amounts of investment from limited funds are usually invested by governments to help develop innovative biotechnology companies. When such companies relocate to another country, a sense of loss often ensues, particularly when public funding has been received. This study sought to understand how NZfounded biotech firms, particularly Dedicated Biotech Firms (DBFs), were relocating from NZ followed by an investigation into the main factors involved in their migration offshore through a qualitative research approach. Firm relocation is complex as it no longer necessarily entails moving physical operations from one location to another. Business functions have become increasingly disaggregated due to advances in communication and information technologies allowing partial relocations to occur. This study found that most NZ-founded DBFs undertook partial relocations. The reasons for relocation stemmed from difficulties in commercialising biotech in NZ. Issues of accessing capital to fund operations, availability of the right personnel and NZ's distance from international markets were the main points identified. Most of the factors were seen to converge on a lack of critical mass in NZ's biotech sector and concurrent cost-disadvantages in developing products and entering foreign markets. A requirement for large amounts of capital for commercialisation was found to be the most prominent feature increasing the likelihood of firms relocating from NZ. Recommendations to overcome the financial challenges of commercialising biotech in NZ included a shift in the investment behaviours of large institutional investment entities to buttress the shortage of capital during late development stages. Alternatively, Government investments could be targeted toward less risky biotech ventures leveraging off existing industries in which NZ is already globally competitive such as agriculture and food. Regardless of the changes that may eventuate, NZ's biotech sector still requires significant growth that can only be achieved organically over time.

Download or read book Evolving Business Models in Biotechnology written by Enal S. Razvi and published by . This book was released on 2000 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Collaborative Value Creation written by Hady Farag and published by Springer Science & Business Media. This book was released on 2009-06-12 with total page 560 pages. Available in PDF, EPUB and Kindle. Book excerpt: Collaboration plays an important role in the early development of com- nies. Among others, they provide opportunities to combine complementary resources, develop additional competencies, and generate valuable signals for investors. They are particularly important for biotechnology firms, whose resource base often is not sufficient to realize the market potential of their R&D findings. Strategic alliances thus are an integral part of the business model of most biotechnology companies, but their economic re- vance is not yet fully understood, since research has thus far neglected most industry-specific drivers of alliance value. Based on an event study, Hady Farag analyzes the capital-market re- tion to alliance-related news announcements and assesses their complex - fects on company value. In this regard, the present work represents the first comprehensive study of European biotechnology alliances. In addition to this unique database, the research approach and techniques in sample - lection, econometric and cross-sectional analyses are state-of-the-art. The author develops and empirically tests an integrative dynamic model of collaborative value drivers. These reflect the specific characteristics of biotechnology firms and biotechnology alliances. Moreover, the work - tends to so far entirely unresearched dynamic aspects of alliances, such as the value of contractual flexibilities, the impact of environmental unc- tainty, and the evolution of alliances over time. Overall, Hady Farag’s work underscores the need to consider pluralistic influences on the value of collaborative ventures.

Download or read book A model for communication about biotechnology written by Bev France and published by BRILL. This book was released on 2006-01-01 with total page 110 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book incorporates two major themes into a model for communication about biotechnology. The first is that of a communicating community, defined as a relatively coherent social group engaging in communication within itself. As biotechnologists do not constitute a unitary group, this book refers to biotechnology communities. Similarly, the broad notion of ‘the public’ is considered to be inadequate, and the notion of distinct public communities is used. The members of each community are considered to have a view of biotechnology made up of their understandings of the nature of science of biotechnology, understandings of the key concepts and models used in biotechnology, perceptions of the nature of risk, and beliefs and attitudes about biotechnology. The second major theme is that of search space. This is the intersection, in a virtual arena, of the components of the ‘views’ of two communities. Where there are elements that are in common to the two, communication in terms of them is possible. Where there is no commonality, the degrees of understanding reached must be used to construct a mutual understanding that may evolve into an agreement.

Download or read book Bioentrepreneurship and Transferring Technology Into Product Development written by Agarwal, Swati and published by IGI Global. This book was released on 2021-06-25 with total page 335 pages. Available in PDF, EPUB and Kindle. Book excerpt: In terms of becoming a successful bioentrepreneur, there is still much more to learn. There are many ways to learn the essential fundamentals of entrepreneurship, including through the mistakes of previous businesses and models. Increased knowledge and a better understanding of what works can be derived from these previous failures and mistakes. Additionally, learning from other bioentrepreneurs can help businesses run successfully. By looking deeper into business models, product development, the fundamental concepts of bioentrepreneurship, and the essential characteristics of bioentrepreneurs, one can become better equipped to understand the role of biological sciences in entrepreneurship, specifically the role of product development. Bioentrepreneurship and Transferring Technology Into Product Development provides a comprehensive understanding of the role of biological sciences, specifically in transforming technology into commercial product. This book compiles the theoretical and practical aspects of bioentrepreneurship and discusses the various factors, including creating business plans, acquiring funding, and successful business models. The chapters also cover areas such as small-scale product development, intellectual property rights, funding schemes for start-ups, and new prospective biotechnology product development. This book is essential for bioentrepreneurs, entrepreneurs, product developers, scientists, practitioners, researchers, academicians, and students interested in product development from a biological science perspective.

Download or read book Key Considerations for a Biotechnology Accelerator written by Kaushala Ratnayake and published by . This book was released on 2017 with total page 72 pages. Available in PDF, EPUB and Kindle. Book excerpt: Many speak of the 21st Century as the Biotech Revolution. Biotechnology accelerator founders feel the industry holds great promise for creating new standards of health, prosperity and sustainability. Biotechnology accelerator programmes are now becoming increasingly prevalent and several are recognised as promising organisations for assisting the development of biotechnology companies. The New Zealand biotechnology industry could potentially benefit from the establishment of a biotechnology accelerator. Adopting a qualitative exploratory methodology, this study explored the key considerations for a biotechnology accelerator within a New Zealand context. This approach was chosen as there is minimal industry research and virtually no academic literature available on biotechnology accelerators. Secondary research reviewed three successful biotechnology accelerators: IndieBio, Biocity Accelerator and OneStart; then fourteen semi-structured interviews were carried out with industry members from the New Zealand biotechnology industry. The secondary findings of the research emphasised collaboration, mentorship, market validation and high intensity learning as keys to existing biotechnology accelerators. Primary findings highlighted the need to expose growing biotechnology companies to experienced individuals, a disconnection across players in the biotechnology industry and the requirement to further educate biotechnology companies on key factors of commercialisation in order develop their sophistication. Exploration of these themes allowed for five key considerations to be shaped, which address the topics of: communal working spaces, mentorship, international networks, commercialisation education and industry endorsement. The Richness, Reach and Receptivity framework provided a useful model to understand the mechanisms through which various aspects of the biotechnology industry and accelerators were affecting developing biotechnology companies. With proposed changes of aligning values and enforcement being added to the framework, the inter-organisational network theory was tailored to the research.

Download or read book A Hybrid Business Model Based on Strategic Partnerships Allows Biotechnology Companies to Bring Treatments to Patients Quicker and More Efficiently written by Ryan Christopher Grabert and published by . This book was released on 2013 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: